Another methodology for designing safer T-cell engager is by targeting tumor-specific antigens displayed by the major histocompatibility complex (MHC), through engineering a TCE that incorporates a T cell receptor (TCR) that can recognize the tumor antigen-MHC complex. Here, HLA-C is linked to neoplasm.